Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C)

TitleDaclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C)
Publication TypeJournal Article
Year of Publication2019
AuthorsPoordad, F., M. L. Shiffman, W. Ghesquiere, A. Wong, G. D. Huhn, F. Wong, A. Ramji, S. D. Shafran, F. McPhee, R. Yang, and others
JournalAntivir Ther
Volume24
Pagination35–44